ArticleFrontiers in nutrition2025
The impact of glycated hemoglobin trajectories on hypertension risk: a retrospective cohort study.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glycated hemoglobin (HbA1c) reliably reflects long-term glucose control and has been linked to hypertension development. This study investigates the relationship between baseline HbA1c levels, HbA1c trajectories, and hypertension risk. Methods: This retrospective cohort study included 10,138 adults from health screenings at Henan Provincial People's Hospital (January 2018-January 2025). Mean age was 54.03 ± 12.97 years, with 31.44% women and mean follow-up of 43.92 months. We analyzed hypertension incidence across HbA1c groups using Kaplan-Meier curves and identified HbA1c trajectory patterns using latent class trajectory modeling (LCTM). Cox proportional hazards models evaluated associations between baseline HbA1c tertiles, HbA1c trajectories, and hypertension risk. Restricted cubic splines explored dose-response relationships. Results: During follow-up, 3,452 participants (34.05%) developed hypertension. After adjustment, participants in the highest baseline HbA1c tertile had significantly increased hypertension risk versus the lowest tertile (HR = 1.49, 95%CI: 1.31-1.70). LCTM identified three distinct trajectories: low-stable (5.57 ± 0.36%), medium-stable (6.45 ± 0.59%), and high-stable (8.42 ± 1.39%). Compared to low-stable trajectory, medium-stable and high-stable groups showed significantly increased risks (HR = 1.38, 95%CI: 1.24-1.53; HR = 2.71, 95%CI: 2.21-3.32, respectively). Restricted cubic spline analysis revealed a J-shaped relationship with an inflection point at HbA1c = 5.70% ( Conclusion: Elevated baseline HbA1c levels, particularly above 5.70%, and medium-to-high stable HbA1c trajectories significantly increase hypertension risk among adults undergoing health screening. HbA1c could serve as a valuable biomarker for hypertension risk assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.